SEC F	Form 4
-------	--------

FORM	4
------	---

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

U obligat	n 16. Form 4 o tions may con ction 1(b).			File	d pursuan	t to Section 16(a) o	of the Se	ecuriti	es Exchan	iqe Act	t of 193	4			nated av s per res	erage burd ponse:	en 0.5
					or Sec	tion 30(h) of the Ín	vestmer	nt Con	npany Act	of 194	10						
1. Name and Address of Reporting Person [*] Schroeder Theodore R						2. Issuer Name and Ticker or Trading Symbol <u>CADENCE PHARMACEUTICALS INC</u> [of Reportii able) r	Reporting Person(s) to Issuer ble) 10% Owner		
(Last)	(First)	(Middle)		CADX		tion (N4	onth/D				x	Officer below)	(give title		below	(specify)
		HARMACEUT FF DRIVE, SU	1		03/22/2	of Earliest Transac 2007		JIIII/D	ay/fear)					Presic	lent, C	EO	
(Street)					4. If Am	endment, Date of C	Driginal	Filed	(Month/Da	y/Year)	r)	Line)	ividual or J				
SAN DI	EGO (CA	92130										X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)														
			Table I - No	n-Deriv	ative S	ecurities Acqu	uired,	Dis	osed o	of, or	Bene	ficially	Owned				
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I				action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securit Disposed			(A) or 3, 4 and 5)			Form (D) or	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	()	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)
			Table II -			curities Acqui Is, warrants, o	-		-			-	wned				
1 Title of	2.	3. Transaction	3A. Deemed	4		5. Number of 6.	Date Ex	ercisa	ble and	Z. Titl	le and A	mount	8. Price of	9. Numb	er of	10.	11. Natur

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number Derivativ Securitie Acquired or Dispos of (D) (In 3, 4 and 5	e s I (A) sed str.	6. Date Exerc Expiration Da (Month/Day/\	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock option (right to buy)	\$15.13	03/22/2007		A		100,000		(1)	03/21/2017	Common Stock	100,000	(2)	100,000	D	

Explanation of Responses:

1. All of the shares of common stock subject to the option are immediately exercisable. 25% of the total number of shares of common stock subject to the option vest and are no longer subject to the Company's right to repurchase on March 22, 2008. 1/48th of the total number of shares of common stock subject to the option vest and are no longer subject to the Company's right to repurchase on the 1st of each month thereafter.

2. Not applicable to this transaction.

Remarks:

/s/ Jennifer M. Repine, Attorney-in-fact

03/26/2007

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.